Tracers / [211At]At-astatophenethylsuccinamate
[211At]At-astatophenethylsuccinamate
Also written as [At-211]astatophenethylsuccinamate
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- N-succinimidyl ester linker reagent for 211At protein/antibody radiolabeling (astatophenethylsuccinamate, SAPS)
- Target / mechanism
- IL-2 receptor alpha-chain (IL-2Ralpha) via humanized anti-Tac antibody PMID 11578907
- Clinical application
- Radioimmunotherapy of cancer using antibody conjugates (e.g., anti-HER2 Herceptin, anti-Tac antibody) in xenograft models PMID 11578907
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | succinimidyl N-2-(4-tributylstannylphenethyl)succinamate (1) | 16720238 2006 Nucl Med Biol |
Need this precursor?We can point you to suppliers for [211At]At-astatophenethylsuccinamate, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.